BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/26/2021 5:51:27 PM | Browse: 733 | Download: 2077
 |
Received |
|
2021-05-03 03:06 |
 |
Peer-Review Started |
|
2021-05-03 03:09 |
 |
First Decision by Editorial Office Director |
|
2021-05-27 18:12 |
 |
Return for Revision |
|
2021-05-30 03:32 |
 |
Revised |
|
2021-06-28 08:38 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2021-08-23 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2021-08-23 08:00 |
 |
Articles in Press |
|
2021-08-23 08:00 |
 |
Edit the Manuscript by Language Editor |
|
2021-09-05 20:31 |
 |
Typeset the Manuscript |
|
2021-11-23 01:56 |
 |
Publish the Manuscript Online |
|
2021-11-26 17:51 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Surgery |
| Manuscript Type |
Retrospective Study |
| Article Title |
Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sarang Hong, Ki Byung Song, Dae Wook Hwang, Jae Hoon Lee, Woohyung Lee, Eunsung Jun, Jaewoo Kwon, Yejong Park, Seo Young Park, Naru Kim, Dakyum Shin, Hyeyeon Kim, Minkyu Sung, Yunbeom Ryu and Song Cheol Kim |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ki Byung Song, MD, PhD, Associate Professor, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. mtsong21c@amc.seoul.kr |
| Key Words |
Pancreatic ductal adenocarcinoma; Early recurrence; Upfront surgery; Carbohydrate antigen 19-9; Adjuvant chemotherapy |
| Core Tip |
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a poor prognosis. Only a minority people get operation due to the advancement of disease and recurrence, which is one of important prognostic factors, often occurs even after surgical resection. We identified the factors associated with the early recurrence of early-stage PDAC evaluating 407 patients with stage I PDAC undergoing upfront surgical resection. Early recurrence was defined as a disease recurrence within 6 mo of surgery. Preoperative carbohydrate antigen 19-9 level of > 70 U/mL determined by receiver operating characteristic analyses was a significant risk factor for early recurrence in early-stage PDAC. |
| Publish Date |
2021-11-26 17:51 |
| Citation |
Hong S, Song KB, Hwang DW, Lee JH, Lee W, Jun E, Kwon J, Park Y, Park SY, Kim N, Shin D, Kim H, Sung M, Ryu Y, Kim SC. Preoperative serum carbohydrate antigen 19-9 Levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. World J Gastrointest Surg 2021; 13(11): 1423-1435 |
| URL |
https://www.wjgnet.com/1948-9366/full/v13/i11/1423.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v13.i11.1423 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.